Central Nervous System Opportunistic Infections

 

 Buy Article Permissions and Reprints

Abstract

Opportunistic infections of the central nervous system are classically associated with immunosuppression arising from infection with human immunodeficiency virus and with various hematologic malignancies. However, over the past few years, they are increasingly associated with transplantation and various immunosuppressive treatments used to treat autoimmune diseases. They cause significant morbidity and mortality and remain a diagnostic challenge due to the absence of typical signs and symptoms of infection and mimicry by various noninfectious causes. The pathogens associated with these infections are often commonly found pathogens of low virulence in immunocompetent hosts and include various bacteria, parasites, fungi, or viruses. These infections can present as various clinical syndromes, including meningitis, encephalitis, space-occupying lesions, stroke-like presentations, or even neoplastic manifestations. Progressive multifocal leukoencephalopathy can be seen in patients with multiple sclerosis on various new immunomodulatory drugs in addition to patients with human immunodeficiency virus, transplantation, or hematologic malignancies, and is characterized by multifocal white matter lesions. Human herpesvirus-6 causes severe encephalitis in transplant recipients, known as posttransplantation acute limbic encephalitis. Neoplastic manifestations like Epstein–Barr virus-associated primary central nervous system lymphoma and posttransplantation lymphoproliferative disorders are particularly challenging to diagnose and manage. Modern diagnostic techniques, including advanced imaging techniques like magnetic resonance spectroscopy, use of polymerase chain reaction, and metagenomic sequencing, can be helpful in early recognition of pathogens. Treatment of most of these involves lowering of immunosuppression when possible and use of specific antimicrobial agents when available. Improved outcomes can be seen when early diagnosis is made.

• References

• 1 Williamson EML, Berger JR. Diagnosis and treatment of progressive multifocal leukoencephalopathy associated with multiple sclerosis therapies. Neurotherapeutics 2017; 14 (04) 961-973
  CrossrefPubMedGoogle Scholar
• 2 Buonomo AR, Zappulo E, Viceconte G, Scotto R, Borgia G, Gentile I. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf 2018; 17 (07) 709-717
  CrossrefPubMedGoogle Scholar
• 3 Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009; 60 (12) 3761-3765
  CrossrefPubMedGoogle Scholar
• 4 Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 2017; 12: 59-63
  CrossrefPubMedGoogle Scholar
• 5 Agnihotri SP, Dang X, Carter JL. , et al. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Neurology 2014; 83 (08) 727-732
  CrossrefPubMedGoogle Scholar
• 6 Agnihotri SP, Wuthrich C, Dang X. , et al. A fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient. Ann Neurol 2014; 76 (01) 140-147
  CrossrefPubMedGoogle Scholar
• 7 Wüthrich C, Dang X, Westmoreland S. , et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol 2009; 65 (06) 742-748
  CrossrefPubMedGoogle Scholar
• 8 Vendrely A, Bienvenu B, Gasnault J, Thiebault JB, Salmon D, Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 2005; 109 (04) 449-455
  CrossrefPubMedGoogle Scholar
• 9 Lima MA, Drislane FW, Koralnik IJ. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 2006; 66 (02) 262-264
  CrossrefPubMedGoogle Scholar
• 10 Bag AK, Curé JK, Chapman PR, Roberson GH, Shah R. JC virus infection of the brain. AJNR Am J Neuroradiol 2010; 31 (09) 1564-1576
  CrossrefPubMedGoogle Scholar
• 11 Yousry TA, Pelletier D, Cadavid D. , et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012; 72 (05) 779-787
  CrossrefPubMedGoogle Scholar
• 12 Wattjes MP, Wijburg MT, Vennegoor A. , et al; Dutch-Belgian Natalizumab-associated PML study group MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. J Neurol Neurosurg Psychiatry 2016; 87 (08) 879-884
  CrossrefPubMedGoogle Scholar
• 13 Berger JR, Pall L, Lanska D, Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 1998; 4 (01) 59-68
  CrossrefPubMedGoogle Scholar
• 14 Berger JR, Aksamit AJ, Clifford DB. , et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80 (15) 1430-1438
  CrossrefPubMedGoogle Scholar
• 15 Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 2005; 43 (08) 4175-4177
  CrossrefPubMedGoogle Scholar
• 16 Clifford DB, Yiannoutsos C, Glicksman M. , et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 1999; 52 (03) 623-625
  CrossrefPubMedGoogle Scholar
• 17 Casado JL, Corral I, García J. , et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis 2014; 33 (02) 179-187
  CrossrefPubMedGoogle Scholar
• 18 Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9 (04) 438-446
  CrossrefPubMedGoogle Scholar
• 19 Harel A, Horng S, Gustafson T, Ramineni A, Farber RS, Fabian M. Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia. J Neurovirol 2018; 24 (05) 652-655
  CrossrefPubMedGoogle Scholar
• 20 Giacomini PS, Rozenberg A, Metz I, Araujo D, Arbour N, Bar-Or A. ; Maraviroc in Multiple Sclerosis–Associated PML–IRIS (MIMSAPI) Group Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome. N Engl J Med 2014; 370 (05) 486-488
  CrossrefPubMedGoogle Scholar
• 21 Rodríguez M, Silva-Sánchez FA, Luna-Rivero C, Vega-Barrientos R, Alvarado-de la Barrera C, Reyes-Terán G. Maraviroc failed to control progressive multifocal leukoencephalopathy-associated IRIS in a patient with advanced HIV infection. Case Rep Med 2014; 2014: 381480
  PubMedGoogle Scholar
• 22 Okuno T, Takahashi K, Balachandra K. , et al. Seroepidemiology of human herpesvirus 6 infection in normal children and adults. J Clin Microbiol 1989; 27 (04) 651-653
  CrossrefPubMedGoogle Scholar
• 23 Hill JA, Venna N. Human herpesvirus 6 and the nervous system. Handb Clin Neurol 2014; 123: 327-355
  PubMedGoogle Scholar
• 24 Hall CB, Long CE, Schnabel KC. , et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. N Engl J Med 1994; 331 (07) 432-438
  CrossrefPubMedGoogle Scholar
• 25 Hill JA, Koo S, Guzman Suarez BB. , et al. Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant 2012; 18 (11) 1638-1648
  CrossrefPubMedGoogle Scholar
• 26 Mori Y, Miyamoto T, Nagafuji K. , et al. High incidence of human herpes virus 6-associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant 2010; 16 (11) 1596-1602
  CrossrefPubMedGoogle Scholar
• 27 Bhanushali MJ, Kranick SM, Freeman AF. , et al. Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. Neurology 2013; 80 (16) 1494-1500
  CrossrefPubMedGoogle Scholar
• 28 MacMahon EM, Glass JD, Hayward SD. , et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 1991; 338 (8773): 969-973
  CrossrefPubMedGoogle Scholar
• 29 Ammassari A, Cingolani A, Pezzotti P. , et al. AIDS-related focal brain lesions in the era of highly active antiretroviral therapy. Neurology 2000; 55 (08) 1194-1200
  PubMedGoogle Scholar
• 30 Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection. Handb Clin Neurol 2018; 152: 177-186
  PubMedGoogle Scholar
• 31 Forsyth PA, DeAngelis LM. Biology and management of AIDS-associated primary CNS lymphomas. Hematol Oncol Clin North Am 1996; 10 (05) 1125-1134
  CrossrefPubMedGoogle Scholar
• 32 Saylor D. Neurologic complications of human immunodeficiency virus infection. Continuum (Minneap Minn) 2018; 24 (5, Neuroinfectious Disease): 1397-1421
  PubMedGoogle Scholar
• 33 Moulignier A, Lamirel C, Picard H. , et al. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy. Neurology 2017; 89 (08) 796-804
  CrossrefPubMedGoogle Scholar
• 34 Phan TG, O'Neill BP, Kurtin PJ. Posttransplant primary CNS lymphoma. Neuro-oncol 2000; 2 (04) 229-238
  PubMedGoogle Scholar
• 35 Lieberman F, Yazbeck V, Raptis A, Felgar R, Boyiadzis M. Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. J Neurooncol 2012; 107 (02) 225-232
  CrossrefPubMedGoogle Scholar
• 36 O'Neill BP, Schiff D. Post-transplant lymphoproliferative disorders of the central nervous system. Continuum 2004; 10: 48-60
  PubMedGoogle Scholar
• 37 Styczynski J, van der Velden W, Fox CP. , et al; Sixth European Conference on Infections in Leukemia, a joint venture of the Infectious Diseases Working Party of the European Society of Blood and Marrow Transplantation (EBMT-IDWP), the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN) Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 2016; 101 (07) 803-811
  CrossrefPubMedGoogle Scholar
• 38 Styczynski J, Gil L, Tridello G. , et al; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation Response to rituximab-based therapy and risk factor analysis in Epstein Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis 2013; 57 (06) 794-802
  CrossrefPubMedGoogle Scholar
• 39 Meyer T, Franke G, Polywka SK. , et al. Improved detection of bacterial central nervous system infections by use of a broad-range PCR assay. J Clin Microbiol 2014; 52 (05) 1751-1753
  CrossrefPubMedGoogle Scholar
• 40 Wilson MR, O'Donovan BD, Gelfand JM. , et al. Chronic meningitis investigated via metagenomic next-generation sequencing. JAMA Neurol 2018; 75 (08) 947-955
  CrossrefPubMedGoogle Scholar
• 41 Wilson MR, Zimmermann LL, Crawford ED. , et al. Acute West Nile virus meningoencephalitis diagnosed via metagenomic deep sequencing of cerebrospinal fluid in a renal transplant patient. Am J Transplant 2017; 17 (03) 803-808
  CrossrefPubMedGoogle Scholar
• 42 Murkey JA, Chew KW, Carlson M. , et al. Hepatitis E virus-associated meningoencephalitis in a lung transplant recipient diagnosed by clinical metagenomic sequencing. Open Forum Infect Dis 2017; 4 (03) ofx121
  CrossrefPubMedGoogle Scholar
• 43 Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H. Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification. Neurology 2017; 88 (12) 1197-1205
  CrossrefPubMedGoogle Scholar